Trial Profile
An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 22 Jul 2009 Actual patient number (2) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.